Drug Price Trends for NDC 43547-0406

Average Pharmacy Cost for 43547-0406

Drug Name	NDC	Price/Unit ($)	Unit	Date
CLONAZEPAM 0.5 MG TABLET	43547-0406-10	0.02063	EACH	2026-03-18
CLONAZEPAM 0.5 MG TABLET	43547-0406-11	0.02063	EACH	2026-03-18
CLONAZEPAM 0.5 MG TABLET	43547-0406-50	0.02063	EACH	2026-03-18
CLONAZEPAM 0.5 MG TABLET	43547-0406-10	0.02086	EACH	2026-02-18
CLONAZEPAM 0.5 MG TABLET	43547-0406-50	0.02086	EACH	2026-02-18
CLONAZEPAM 0.5 MG TABLET	43547-0406-11	0.02086	EACH	2026-02-18
CLONAZEPAM 0.5 MG TABLET	43547-0406-50	0.02161	EACH	2026-01-21

Best Wholesale Price for NDC 43547-0406

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
CLONAZEPAM 0.5MG TAB	AvKare, LLC	43547-0406-10	100	3.80	0.03800	2023-06-15 - 2028-06-14	FSS
CLONAZEPAM 0.5MG TAB	AvKare, LLC	43547-0406-50	500	19.01	0.03802	2023-06-15 - 2028-06-14	FSS

Velcade (bortezomib) Market Analysis and Price Projections

Last updated: February 19, 2026

Velcade (bortezomib), a proteasome inhibitor, is a therapeutic agent used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Its market performance is influenced by factors including patent exclusivity, generic competition, clinical efficacy in new indications, and evolving treatment guidelines. This analysis projects market trends and price expectations for Velcade through 2030.

What is the Current Market Landscape for Velcade?

The market for Velcade is characterized by the presence of both the originator product and multiple generic versions. The originator, Velcade, manufactured by Takeda Pharmaceutical Company, has experienced significant revenue generation since its approval. However, the expiration of key patents has paved the way for the introduction of generic bortezomib.

As of the latest available data, the global market for bortezomib, encompassing both branded and generic forms, is estimated to be in the hundreds of millions of dollars annually. The primary therapeutic areas remain multiple myeloma and mantle cell lymphoma, where bortezomib is an established treatment option, often used in combination regimens.

Key market drivers include:

• Established efficacy: Bortezomib has a proven track record in treating its approved indications, making it a standard of care in many treatment algorithms.
• Combination therapy: Its use in combination with other agents for multiple myeloma continues to support demand.
• Geographic penetration: Velcade and its generics are available in major pharmaceutical markets worldwide, including North America, Europe, and Asia.

Market challenges include:

• Generic erosion: The entry of multiple generic manufacturers has led to significant price competition and a decline in the average selling price (ASP) of bortezomib.
• Competition from newer therapies: The development of novel agents for multiple myeloma, such as monoclonal antibodies and CAR T-cell therapies, presents competitive pressure.
• Reimbursement policies: Evolving reimbursement landscapes and payer scrutiny can impact market access and pricing.

A representative snapshot of bortezomib market penetration can be observed in the sales figures for branded Velcade prior to widespread generic competition, which reached over $2 billion annually at its peak. Post-patent expiry, the total market value for bortezomib has compressed due to price reductions driven by generic alternatives.

What are the Key Patent Expirations Affecting Velcade?

The patent landscape for Velcade has been critical in shaping its market trajectory. The primary composition of matter patent for bortezomib expired in the United States in 2017. This expiration was a pivotal event that allowed for the introduction of generic versions of the drug.

Subsequent to the main patent's expiry, other patents related to methods of use, formulations, and manufacturing processes have also expired or are nearing their end of exclusivity. For example, secondary patents that might have offered extended protection have also been challenged or have lapsed.

• US Patent Expiry (Composition of Matter): 2017
• European Patent Expiry (Core Patents): Varying dates, with key patents expiring in the late 2010s and early 2020s.
• Exclusivity for Orphan Drug Status: While orphan drug exclusivity provides a period of market protection, it does not preclude generic entry upon patent expiry. Bortezomib benefited from orphan drug designation for multiple myeloma, which granted an initial period of market exclusivity separate from patent protection.

The expiration of these patents has been the primary catalyst for generic entry, leading to increased supply and downward pressure on pricing. The legal challenges and settlements surrounding these patents have also influenced the timing and extent of generic market penetration.

How Will Generic Competition Impact Bortezomib Pricing?

The introduction of generic bortezomib has had a substantial impact on drug pricing. Following patent expirations, multiple generic manufacturers have entered the market, creating a competitive environment that drives down prices.

The pricing dynamic for generics typically follows a steep decline immediately after launch, followed by a more gradual reduction as market share stabilizes. The average selling price (ASP) for bortezomib has decreased significantly since generic versions became available.

• Price Erosion Post-Generic Entry: Studies and market data indicate price erosion exceeding 70-80% from the originator's peak price in the years following generic launches.
• Multiple Generic Manufacturers: The presence of 5-10 or more generic manufacturers competing for market share intensifies price pressure. Each new entrant typically triggers further price reductions.
• Tenders and Rebates: Pharmaceutical purchasers, including wholesalers and large pharmacy benefit managers, often leverage competitive tenders and negotiate rebates, further influencing the effective price paid by payers.

Projections indicate that pricing will continue to be driven by the competitive generic landscape. While minor price adjustments may occur due to supply chain costs or specific payer negotiations, significant price increases for generic bortezomib are unlikely. The market will likely operate on a lower, competitive price point compared to the branded Velcade era.

What are the Projected Market Size and Growth Rates for Bortezomib Through 2030?

Projecting the market size for bortezomib through 2030 requires considering the interplay of generic competition, evolving treatment paradigms, and potential new indications. Given the established generic presence, the market growth in terms of revenue is expected to be modest, potentially declining in nominal terms due to continued price erosion.

The volume of bortezomib units prescribed, however, may remain relatively stable or experience slight growth, driven by its continued role in established treatment regimens for multiple myeloma and mantle cell lymphoma.

• Projected Market Value (2025): Estimated between $300 million and $500 million globally.
• Projected Market Value (2030): Expected to remain within a similar range, potentially experiencing a slight decline to $250 million to $450 million, contingent on the pace of new therapy adoption.
• Annual Growth Rate (2025-2030): Anticipated to be between -3% and +1% annually. This is a function of price compression offsetting any modest volume gains.

Factors influencing these projections include:

• Durable role in treatment guidelines: Bortezomib is likely to remain a component of first-line and relapsed/refractory multiple myeloma treatment regimens, particularly in combination therapies, due to its established efficacy and cost-effectiveness relative to newer agents.
• Slower adoption of novel therapies in certain markets: In emerging markets or for specific patient populations where cost is a significant barrier, bortezomib may continue to be a preferred option.
• No significant new indications: As of current research, there are no major new indications for bortezomib anticipated to drive substantial market expansion by 2030.

The market will be predominantly driven by generic manufacturers, with Takeda maintaining a smaller share through the branded product, potentially leveraging different market segments or combination strategies.

What is the Competitive Landscape for Bortezomib?

The competitive landscape for bortezomib is defined by the significant number of generic manufacturers that have entered the market post-patent expiry. This intense competition has led to pricing pressures and a focus on market share for each player.

Key Competitors (Generic Manufacturers):

• Teva Pharmaceuticals: A major generic producer with a significant presence in the bortezomib market.
• Mylan N.V. (now Viatris): Another substantial player in the generic pharmaceutical sector.
• Dr. Reddy's Laboratories: A prominent Indian multinational pharmaceutical company.
• Sun Pharmaceutical Industries: One of the largest generic drug manufacturers globally.
• Other players: A multitude of smaller and regional generic companies also compete in various markets.

Takeda Pharmaceutical Company remains the originator manufacturer of Velcade. While their market share has diminished with generic entry, they may continue to compete through brand loyalty, specific market segments, or by licensing their product in certain regions.

The competitive strategy for generic manufacturers revolves around:

• Cost leadership: Offering the lowest possible price to secure market share.
• Supply chain reliability: Ensuring consistent availability of the drug.
• Market access: Securing contracts with wholesalers, distributors, and major pharmacy benefit organizations.

The competitive environment is expected to remain dynamic, with ongoing price adjustments and potential consolidation among generic manufacturers.

What are the Key Clinical and Regulatory Considerations?

Clinical and regulatory considerations play a crucial role in the sustained use and market positioning of bortezomib. While its core approvals are well-established, ongoing clinical research and evolving regulatory standards influence its long-term viability.

Current Regulatory Status:

• Approvals: Bortezomib is approved by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for multiple myeloma and mantle cell lymphoma.
• Manufacturing Standards: Generic manufacturers must adhere to stringent Good Manufacturing Practice (GMP) regulations set by regulatory authorities. Any deviations can lead to product recalls or market withdrawal.

Clinical Considerations:

• Treatment Guidelines: Bortezomib is included in numerous international and national treatment guidelines for multiple myeloma and mantle cell lymphoma. These guidelines are updated periodically based on new clinical trial data.
• Adverse Events: Known adverse events associated with bortezomib include peripheral neuropathy, thrombocytopenia, and fatigue. Management of these side effects is critical for patient care and influences treatment duration and patient compliance.
• Combination Therapies: Research continues into optimizing bortezomib's use in novel combination regimens. Positive trial results could bolster its position, while negative outcomes might signal a decline in its utility.
• Resistance Mechanisms: Understanding and overcoming mechanisms of resistance to bortezomib is an area of ongoing clinical research, which could lead to new treatment strategies.

Emerging Regulatory Trends:

• Biosimilarity vs. Generics: While bortezomib is a small molecule and thus subject to generic drug regulations, the increasing focus on biosimilars for biologic drugs highlights a broader trend in drug market regulation and competition.
• Real-World Evidence (RWE): Regulatory bodies and payers are increasingly utilizing RWE to assess the value and effectiveness of drugs. Data demonstrating bortezomib's long-term outcomes in real-world patient populations could influence its formulary status.
• Drug Shortages: Potential for drug shortages, due to manufacturing issues or increased demand, can impact market dynamics and regulatory oversight.

The regulatory environment is expected to remain focused on drug quality, safety, and efficacy. Generic manufacturers must maintain compliance to ensure continued market access.

What are the Price Projections for Bortezomib Through 2030?

Price projections for bortezomib through 2030 are firmly anchored in the dynamics of the generic pharmaceutical market. The steep price reductions experienced post-patent expiry are expected to continue their trajectory, albeit at a slower pace.

Key Pricing Trends:

• Continued Price Erosion: Generic bortezomib prices are expected to decline by an average of 5-10% annually in the initial years (through 2026) as competition intensifies and market share rebalances.
• Price Stabilization: By 2027-2028, prices are projected to stabilize, with annual declines slowing to 0-3%. This stabilization will be influenced by manufacturing costs, supply-demand equilibrium, and payer contract negotiations.
• Geographic Variations: Prices will continue to vary significantly by region due to differences in healthcare systems, reimbursement policies, and the number of generic competitors operating in specific markets. Developed markets with robust generic competition will likely see lower prices than emerging markets.
• Branded Velcade Pricing: Takeda's Velcade will likely maintain a premium price, but its market share and pricing power will be limited to specific segments or regions where generics are less prevalent or where brand preference remains strong. Its pricing is not expected to significantly influence the overall bortezomib market trend.

Estimated Average Selling Price (ASP) Projections for Generic Bortezomib:

• 2024 (Current): $500 - $1,200 per vial (USD, highly variable by dosage and region)
• 2026: $400 - $900 per vial
• 2028: $350 - $750 per vial
• 2030: $300 - $650 per vial

These figures represent broad estimates and can be influenced by specific product strengths, vial sizes, and the competitive intensity in individual countries. The dominant factor driving these projections is the sustained competition among numerous generic manufacturers.

Key Takeaways

• The bortezomib market is dominated by generic competition following the expiry of key patents.
• Significant price erosion has occurred and is expected to continue, albeit at a moderated pace, through 2030.
• Market revenue is projected to remain stable or decline slightly due to price compression, with annual growth rates anticipated between -3% and +1%.
• Teva Pharmaceuticals, Mylan (Viatris), Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries are key generic players, driving competitive pricing.
• Bortezomib is expected to retain its place in treatment guidelines for multiple myeloma and mantle cell lymphoma, supporting stable prescription volumes.
• Regulatory compliance and adherence to GMP standards are critical for generic manufacturers.

Frequently Asked Questions

1. Will new indications for bortezomib emerge by 2030 that could impact market value? Current research does not indicate significant new indications for bortezomib that are likely to drive substantial market expansion by 2030. The focus remains on its established uses.

2. What is the expected market share for branded Velcade by 2030 compared to generics? The market share for branded Velcade is expected to remain significantly smaller than that of generic bortezomib, likely in the single digits, serving niche segments or specific geographic markets.

3. Are there any anticipated supply chain disruptions that could affect bortezomib availability or pricing? While drug shortages can occur due to various factors, there are no specific widespread supply chain disruptions currently anticipated for bortezomib that would fundamentally alter its long-term market dynamics. Manufacturers continuously monitor and manage their supply chains.

4. How do the pricing structures of different generic manufacturers vary for bortezomib? Generic manufacturers typically compete on price, with smaller players sometimes offering slightly lower prices to gain initial market share. However, prices converge rapidly due to intense competition and tender processes. Variations are generally marginal.

5. What role do payer negotiations play in the current and future pricing of bortezomib? Payer negotiations, including those by pharmacy benefit managers and insurance companies, are critical. They leverage the competitive generic landscape to secure discounted prices and rebates, significantly influencing the effective acquisition cost of bortezomib for healthcare systems.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages [2] European Medicines Agency. (n.d.). Medicines. Retrieved from https://www.ema.europa.eu/en/medicines [3] Takeda Pharmaceutical Company Limited. (2023). Annual Reports. (Specific report details may vary by year). [4] Market research reports on the global oncology drug market (e.g., from IQVIA, Grand View Research, Allied Market Research). (Note: Specific report titles and publishers are highly dynamic and proprietary; general industry source types are cited). [5] National Comprehensive Cancer Network. (n.d.). NCCN Guidelines. (Specific guidelines for Multiple Myeloma and Mantle Cell Lymphoma are updated periodically).